Omeros adds Joseph Schocken to board of directors
Omeros Corporation expanded its board to nine members and appointed the investor and Broadmark Capital founder effective August 12, 2026.
SEC filing
Latest
2 stories
Thursday, August 13
Wednesday, August 12
Omeros reports Q2 2026 results as YARTEMLEA sales climb and CHMP issues negative opinion
Omeros posted strong U.S. launch revenue for YARTEMLEA while the EMA's CHMP gave a negative opinion on the drug's European application, triggering a re-examination.
SEC filing